Clinical Trials Logo

Locally Advanced Prostate Cancer clinical trials

View clinical trials related to Locally Advanced Prostate Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06387056 Recruiting - Clinical trials for Oligometastatic Prostate Cancer

Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)

SEGNO
Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

To evaluated the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer.

NCT ID: NCT05406999 Recruiting - Neoadjuvant Therapy Clinical Trials

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

Start date: February 1, 2020
Phase: Phase 2
Study type: Interventional

This is a prospective, multicenter, multi-arm, non-randomized, open-label clinical trial to evaluate the efficacy and safety of neoadjuvant intense endocrine therapy for high-risk or locally advanced prostate cancer.

NCT ID: NCT01048151 Recruiting - Clinical trials for Locally Advanced Prostate Cancer

TNFerade Biologic to Treat Locally Advanced Prostate Cancer

Start date: n/a
Phase: Phase 1
Study type: Interventional

While radiation therapy with androgen ablation (hormone reduction) is the standard method of treating locally advanced prostate cancer. New treatments are being combined with radiation therapy in an effort to further improve the cure rates. This study proposes to combine an experimental drug, TNFeradeā„¢ Biologic, (also called AdGVEGR.TNF.11D or "TNFerade") at different dose (amounts) levels in combination with radiation. TNFeradeā„¢ Biologic is a form of gene transfer therapy that when injected into the tumor has shown to increase the effect of radiation therapy.